Jim Cramer Says “CRISPR (CRSP) Keeps Losing Money Like Moderna” – Here’s Why
We recently published a list of 9 Stocks Jim Cramer Talked About. In this article, we are going to take a look at where ...
STAT1d
Pharmalittle: We’re reading about FDA OK for Vertex non-opioid pain drug, vaccine advisory committee, and more
Vertex Pharmaceuticals won approval from the U.S. Food and Drug Administration for a non-opioid pain drug, clearing the way ...
Tal Zaks's Israeli startup targets rare genetic diseases
"This type of gene editing should also allow for the treatment of diseases whose origin is not genetic or whose origin cannot ...
STAT2d
Vertex, U.K. reach reimbursement deal for CRISPR-based medicine for sickle cell disease
People in England with sickle cell will be able to get the world’s first CRISPR-based medicine under an agreement between the ...
From Underperformance To Opportunity: Biotech's Case For 2025
Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...
BBC19d
The mystery of why Covid-19 seems to be becoming milder
Covid-19 is now ubiquitous – but hospitalisations seem to be on a downward trajectory. No one knows why. When virologists took their first peek at XEC, the Covid-19 variant which started to ...
Escaping the endosome: BEND lipids improve LNP mRNA delivery and gene editing
Every time a shuttle docks with the International Space Station (ISS), a delicate dance unfolds between the shuttle's docking ...
Seeking Alpha17d
CRISPR Therapeutics: Unfairly Punished By The Issues Of Its Peers
CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic ...